Latest Dendritic cell Stories

Amplification of RCC RNA Evaluated Using Newly Developed Techniques DURHAM, N.C., May 8, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company's improved RNA...

Heidi M. Hagen, a noted authority on Biotech Cell Manufacturing, Joins as Head of Global Operations Strategy NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which...

PALO ALTO, Calif., March 21, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) announced that in the first week of March 2013, the company launched a clinical trial for TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. The clinical trial, which is already in progress, is the result of collaboration between CBMG, California Stem Cell (CSC) and Shanghai's PLA 85 Hospital. It is the first...

Next Generation Technology Already In DCVax®-Direct; Will Be Applicable To All DCVax® Products BETHESDA, Md., March 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued a key U.S. patent (#8389278) covering novel processes for manufacturing human dendritic cells. The cells produced through these processes are much more...

DURHAM, N.C., Jan. 15, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate. AGS-003 is an investigational, fully personalized, dendritic-cell...

Scientists from the AIDS Research Institute IrsiCaixa have identified how HIV, the virus that causes AIDS, enters the cells of the immune system enabling it to be dispersed throughout an organism. The new study is published December 18 in the open access journal PLOS Biology. One of the reasons why we do not yet have a cure for HIV infection is that the virus infects cells of the immune system that would normally fight such an infection. The main targets of HIV are white blood cells named...

Researchers at the University of California, San Diego School of Medicine report that tumor cells use stress signals to subvert responding immune cells, exploiting them to actually boost conditions beneficial to cancer growth. The findings are published in the December 18 online issue of the journal PLOS ONE. Lead author Navin R. Mahadevan, a graduate student in the Laboratory of Immunology at the UC San Diego Moores Cancer Center, and colleagues found that tumor cells manipulate a...

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism. The findings, published in Nature Immunology today (30 September), could be exploited in vaccine development and new cancer therapies. A healthy immune system reacts to danger signals – from microorganisms such as bacteria and viruses, or from the...

WOONSOCKET, R.I., Sept. 27, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the acceptance by the American Society for Cell Biology® (ASCB®) of abstract "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma." The preclinical research results will be presented by Anand Ghanekar M.D., Ph.D., Division of Cellular & Molecular Biology, Toronto General Hospital...

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source – providing a new potential target for vaccines for conditions such as cancer or Hepatitis B. Publishing in the journal Immunity, the team of researchers from Newcastle University in collaboration with A*STAR's Singapore Immunology Network (SIgN) describe a new human tissue dendritic cell with cross-presenting function. Dendritic cells...